|
Deferred Research And Development Arrangement (Details) (USD $)
|
3 Months Ended | 12 Months Ended | 3 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2014
|
Dec. 31, 2013
|
Mar. 31, 2014
Rexgene [Member]
|
Mar. 31, 2013
Rexgene [Member]
|
Dec. 31, 2003
Rexgene [Member]
|
Dec. 31, 2013
Rexgene [Member]
|
Mar. 31, 2014
Teva Pharmaceutical Industries, Ltd. [Member]
|
Mar. 31, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
|
Dec. 31, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
|
Nov. 27, 2012
Teva Pharmaceutical Industries, Ltd. [Member]
|
|
| Research and development arrangement, one-time fee | $ 1,500,000 | |||||||||
| Reduction of research and development expenses | 18,750 | 18,750 | 32,600 | 134,621 | ||||||
| Deferred Research and Development Arrangement | 782,280 | 833,630 | 656,250 | 675,000 | 126,030 | 158,630 | ||||
| Royalties paid, percentage of net sales | 3.00% | |||||||||
| Restricted Cash and Cash Equivalents, Noncurrent | $ 163,530 | $ 196,130 | $ 926,000 | |||||||
| X | ||||||||||
|
- Definition
The unexpensed portion of deferred research and development arrangement as of the balance sheet date. Deferred research and development arrangement is a liability related to a collaborative research agreement. Generally, an entity records deferred research and development arrangement when it receives consideration from a collaborator, and expenses the contribution over a period of time. No definition available.
|
| X | ||||||||||
|
- Definition
Research And Developement Agreement Period Expense Reduction Amount No definition available.
|
| X | ||||||||||
|
- Definition
Research And Developement Agreement Royalty Percentage Of Net Sales No definition available.
|
| X | ||||||||||
|
- Definition
The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|